GSK Highlights Easy Pen Delivery Of Albiglutide As FDA Begins Review
This article was originally published in Pharmaceutical Approvals Monthly
The GLP-1 class is set for huge growth in the diabetes market, but competition is going to be tough. GlaxoSmithKline explains why its newly submitted once-weekly GLP-1 agonist albiglutide has what it takes to succeed.
You may also be interested in...
Britain’s biggest drug maker updated the investment community on its pipeline prospects Dec. 3, outlining a timescale of three pipeline “waves” that will include pivotal clinical trial results on up to 14 medicines in the next two years.
New treatments for Type 2 diabetes are driving the optimism underlying Bristol and AstraZeneca’s proposed acquisition for Amylin and are leading to a re-alignment of allies and competitors focused on the disease. Companies are enthusiastic about the vast opportunity, yet worried about the costs and risks of full-scale commitment to it.
Bristol-Myers and AstraZeneca’s acquisition of Amylin as part of a 50-50 collaboration brings a big new player into the fast-growing GLP-1 class, which is emerging as a key component of treatment in the large, but highly competitive Type 2 diabetes market.